Y-mAbs Announces Pivotal Data for Omburtamab
October 03, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
September 26, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab
September 01, 2022 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma
August 30, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the...
Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments
August 08, 2022 16:05 ET
|
Y-mAbs Therapeutics, Inc
Omburtamab BLA Accepted by the FDA with November 2022 PDUFA date Announced IND Clearance for the first GD2-SADA construct YTD DANYELZA® product revenue $20.3 millionManagement reiterates financial...
Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022
August 02, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended...
Y-mAbs’ Announces Clearance of IND for GD2-SADA
July 12, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review
May 31, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint
May 26, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
May 09, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
Completed resubmission to the FDA of omburtamab BLADANYELZA® adoption drove a 9% sequential revenue increase to $10.5 millionCompany issues 2022 full-year DANYELZA® revenue guidance of $45-$50...